✦ LIBER ✦

Immunological complications in multiple sclerosis patients receiving interferon

✍ Scribed by Dr. G. P. A. Rice; E. L. Woelfel; P. J. Talbot; S. L. Braheny; J. C. Sipe; R. L. Knobler; T. C. Merigan; M. B. A. Oldstone

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 371 KB
Volume: 18
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.410180405

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serial immunological studies in multiple

Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon

✍ Dr. Hillel S. Panitch; Gordon S. Francis; Carol J. Hooper; Thomas C. Merigan; Ke 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB 👁 2 views

Defining interferon β response status in

Defining interferon β response status in multiple sclerosis patients

✍ Richard A. Rudick; Jar-Chi Lee; Jack Simon; Richard M. Ransohoff; Elizabeth Fish 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 1 views

Use of interferon in multiple sclerosis

✍ Dale E. McFarlin 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB 👁 2 views

Defining the response to interferon-β in

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

✍ Jordi Río; Carlos Nos; Mar Tintoré; Nieves Téllez; Ingrid Galán; Raúl Pelayo; Ma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

Pegylated-interferon induced severe bone

Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myeloma receiving thalidomide

✍ J. David Gómez-Rangel; Guillermo J. Ruiz-Delgado; Guillermo J. Ruiz-Argüelles 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Identify of interferon-β1a product in mu

Identify of interferon-β1a product in multiple sclerosis study

✍ Wieland W. Wolf 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

We extend sincere congratulations to Dr Jacobs and colleagues for the successful conclusion of their study of recombinant interferon p l a (rIFN-pla) in patients with multiple sclerosis (MS). The impressive results showed that 6 million international units of rIFN-Pla applied once weekly via the int